Core Viewpoint - Sangamo Therapeutics (688336.SH) reported a significant increase in performance for 2025, primarily due to a collaboration with Pfizer, resulting in a revenue of 4.199 billion yuan, a 251.81% increase year-on-year, and a net profit of 2.939 billion yuan, a 317.09% increase year-on-year [1] Group 1: Financial Performance - Sangamo Therapeutics achieved a total revenue of 4.199 billion yuan in 2025, marking a 251.81% increase compared to the previous year [1] - The company reported a net profit attributable to shareholders of 2.939 billion yuan, reflecting a year-on-year growth of 317.09% [1] - The adjusted net profit, excluding government subsidies and other non-operating income, reached 2.805 billion yuan, with an astonishing increase of 1041.01% [1] Group 2: Collaboration with Pfizer - The significant revenue increase was largely attributed to a key collaboration with Pfizer, which involved a licensing fee payment of approximately 2.890 billion yuan for the SSGJ-707 project [1] - On May 20, 2025, Sangamo's parent company, Sangamo Pharmaceuticals (01530.HK), signed an agreement with Pfizer granting exclusive global rights (excluding mainland China) for the development, production, and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707 [3] - The agreement includes a non-refundable upfront payment of 1.25 billion USD and potential milestone payments up to 4.8 billion USD [3] Group 3: Market Competition - The PD-1/VEGF bispecific antibody market is becoming increasingly competitive, with multiple entrants and significant attention from various pharmaceutical companies [1][4] - Sangamo Therapeutics plans to focus on core pipeline innovations and differentiated research to enhance long-term value in response to the competitive landscape [2] - As of now, there are 17 PD-(L)1/VEGF bispecific antibodies in clinical trials globally, indicating a crowded and competitive market [4] Group 4: Product Pipeline and Development - Sangamo Therapeutics has a total of 22 projects in its pipeline, with 7 in Phase III clinical trials, including key products targeting autoimmune diseases [6] - The company has received regulatory acceptance for its applications for the recombinant anti-IL-1β monoclonal antibody SSGJ-613 and the anti-IL-4Rα monoclonal antibody SSGJ-611 [6] - The anti-IL-17A monoclonal antibody, Anmucita, was approved for use in moderate to severe plaque psoriasis patients in China [6][7]